Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.
Breast Neoplasms
Drug Therapy, Combination
Immune Evation
Lymphocytes, Tumor-Infiltrating
Macrophages
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
accepted:
21
02
2023
entrez:
8
3
2023
pubmed:
9
3
2023
medline:
11
3
2023
Statut:
ppublish
Résumé
The success of HER2-positive (HER2+) breast cancer treatment with trastuzumab, an antibody that targets HER2, relies on immune response. We demonstrated that TNFα induces mucin 4 (MUC4) expression, which shields the trastuzumab epitope on the HER2 molecule decreasing its therapeutic effect. Here, we used mouse models and samples from HER2+ breast cancer patients to unravel MUC4 participation in hindering trastuzumab effect by fostering immune evasion. We used a dominant negative TNFα inhibitor (DN) selective for soluble TNFα (sTNFα) together with trastuzumab. Preclinical experiments were performed using two models of conditionally MUC4-silenced tumors to characterize the immune cell infiltration. A cohort of 91 patients treated with trastuzumab was used to correlate tumor MUC4 with tumor-infiltrating lymphocytes. In mice bearing de novo trastuzumab-resistant HER2+ breast tumors, neutralizing sTNFα with DN induced MUC4 downregulation. Using the conditionally MUC4-silenced tumor models, the antitumor effect of trastuzumab was reinstated and the addition of TNFα-blocking agents did not further decrease tumor burden. DN administration with trastuzumab modifies the immunosuppressive tumor milieu through M1-like phenotype macrophage polarization and NK cells degranulation. Depletion experiments revealed a cross-talk between macrophages and NK cells necessary for trastuzumab antitumor effect. In addition, tumor cells treated with DN are more susceptible to trastuzumab-dependent cellular phagocytosis. Finally, MUC4 expression in HER2+ breast cancer is associated with immune desert tumors. These findings provide rationale to pursue sTNFα blockade combined with trastuzumab or trastuzumab drug conjugates for MUC4+ and HER2+ breast cancer patients to overcome trastuzumab resistance.
Sections du résumé
BACKGROUND
The success of HER2-positive (HER2+) breast cancer treatment with trastuzumab, an antibody that targets HER2, relies on immune response. We demonstrated that TNFα induces mucin 4 (MUC4) expression, which shields the trastuzumab epitope on the HER2 molecule decreasing its therapeutic effect. Here, we used mouse models and samples from HER2+ breast cancer patients to unravel MUC4 participation in hindering trastuzumab effect by fostering immune evasion.
METHODS
We used a dominant negative TNFα inhibitor (DN) selective for soluble TNFα (sTNFα) together with trastuzumab. Preclinical experiments were performed using two models of conditionally MUC4-silenced tumors to characterize the immune cell infiltration. A cohort of 91 patients treated with trastuzumab was used to correlate tumor MUC4 with tumor-infiltrating lymphocytes.
RESULTS
In mice bearing de novo trastuzumab-resistant HER2+ breast tumors, neutralizing sTNFα with DN induced MUC4 downregulation. Using the conditionally MUC4-silenced tumor models, the antitumor effect of trastuzumab was reinstated and the addition of TNFα-blocking agents did not further decrease tumor burden. DN administration with trastuzumab modifies the immunosuppressive tumor milieu through M1-like phenotype macrophage polarization and NK cells degranulation. Depletion experiments revealed a cross-talk between macrophages and NK cells necessary for trastuzumab antitumor effect. In addition, tumor cells treated with DN are more susceptible to trastuzumab-dependent cellular phagocytosis. Finally, MUC4 expression in HER2+ breast cancer is associated with immune desert tumors.
CONCLUSIONS
These findings provide rationale to pursue sTNFα blockade combined with trastuzumab or trastuzumab drug conjugates for MUC4+ and HER2+ breast cancer patients to overcome trastuzumab resistance.
Identifiants
pubmed: 36889811
pii: jitc-2022-005325
doi: 10.1136/jitc-2022-005325
pmc: PMC10016294
pii:
doi:
Substances chimiques
Trastuzumab
P188ANX8CK
Mucin-4
0
Tumor Necrosis Factor-alpha
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: RS is a consultant for and a research grant from INmune Bio. All other authors declare they have no competing interests.
Références
Crit Rev Oncol Hematol. 2019 Jul;139:53-66
pubmed: 31112882
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Cancer Res. 2021 Mar 1;81(5):1201-1208
pubmed: 33203697
Cancer Cell. 2009 May 5;15(5):429-40
pubmed: 19411071
Brief Bioinform. 2021 Jul 20;22(4):
pubmed: 33320931
Trends Immunol. 2012 Mar;33(3):119-26
pubmed: 22277903
Cancer Cell. 2010 Aug 9;18(2):160-70
pubmed: 20708157
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31689243
Pancreas. 2013 Jul;42(5):813-8
pubmed: 23429495
J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):323-37
pubmed: 11547901
Theranostics. 2022 Jan 1;12(2):842-858
pubmed: 34976216
Br J Cancer. 2006 Jan 30;94(2):259-67
pubmed: 16404427
Clin Cancer Res. 2004 Oct 1;10(19):6528-34
pubmed: 15475440
J Exp Med. 2008 Dec 22;205(13):3007-18
pubmed: 19064698
Nature. 1997 Feb 20;385(6618):729-33
pubmed: 9034190
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
J Immunol. 2015 May 1;194(9):4379-86
pubmed: 25795760
Biomaterials. 2021 Jan;268:120601
pubmed: 33338932
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
Nature. 2019 May;569(7756):428-432
pubmed: 31043740
Ann Oncol. 2019 Mar 1;30(3):418-423
pubmed: 30657852
Leukemia. 2009 May;23(5):912-8
pubmed: 19225537
Nature. 2003 Feb 13;421(6924):756-60
pubmed: 12610629
Science. 2003 Sep 26;301(5641):1895-8
pubmed: 14512626
Cancer Immunol Res. 2016 May;4(5):441-51
pubmed: 26896171
Clin Cancer Res. 2017 Feb 1;23(3):636-648
pubmed: 27698002
Nat Rev Immunol. 2014 Feb;14(2):94-108
pubmed: 24445665
Int J Cancer. 2002 Jun 20;99(6):783-91
pubmed: 12115478
J Clin Oncol. 2021 Dec 20;39(36):4073-4126
pubmed: 34724392
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
Cancer Immunol Immunother. 2017 Apr;66(4):523-535
pubmed: 28184968
Cancer Cell. 2016 Dec 12;30(6):925-939
pubmed: 27866850
Blood. 2007 Apr 15;109(8):3333-41
pubmed: 17164346
Blood. 2010 Aug 12;116(6):926-34
pubmed: 20439625
Science. 2013 Sep 13;341(6151):1192-8
pubmed: 24031011
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Neoplasia. 2020 Nov;22(11):539-553
pubmed: 32966956
Mol Cancer Ther. 2003 May;2(5):445-51
pubmed: 12748306
J Pharmacol Exp Ther. 2002 May;301(2):418-26
pubmed: 11961039
Breast. 2022 Feb;61:136-144
pubmed: 34999427
Bioinformatics. 2017 Mar 1;33(5):693-700
pubmed: 28062443
Clin Cancer Res. 2021 Feb 15;27(4):1037-1047
pubmed: 33272982
JAMA Oncol. 2015 Jul;1(4):448-54
pubmed: 26181252
Biotechnol J. 2014 Jun;9(6):844-51
pubmed: 24806546
J Biol Chem. 1999 Feb 26;274(9):5263-6
pubmed: 10026131
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Lancet Oncol. 2014 Feb;15(2):e58-68
pubmed: 24480556
Lancet Oncol. 2014 May;15(6):640-7
pubmed: 24657003